¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"infection control study"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • retrospective cohort study
    ÈÄÇâÄÚȣƮ¿¬±¸
  • retrospective study
    ÈÄÇ⿬±¸
  • study
    1. ¿¬±¸, Á¶»ç 2. °Ë»ç, °Ë»ö
  • study design
    ¿¬±¸¼³°è
  • single blind study
    ´ÜÀϸͰ˿¬±¸
  • urodynamic study
    ¿ä¿ªµ¿Çа˻ç
  • video-urodynamic study
    ¿µ»ó¿ä¿ªµ¿Çа˻ç
  • accuracy control
    Á¤È®µµ°ü¸®
  • awaking drug control law
    °¢¼ºÁ¦Á¶Àý¹ý
  • air pollution control
    ´ë±â¿À¿°°ü¸®
  • biologics control laboratory
    »ý¹°Á¦Á¦°ü¸®½ÃÇè¼Ò
  • birth control
    »ê¾ÆÁ¦ÇÑ
  • bite control
    ±³ÇÕÁ¶Á¤
  • communicable disease control
    Àü¿°º´°ü¸®
  • conception control
    ¼öÅÂÁ¶Àý
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • neonatal infection
    °«³­¾Ö°¨¿°, ½Å»ý¾Æ°¨¿°
  • opportunistic infection
    ±âȸ°¨¿°
  • oral infection
    ÀԾȰ¨¿°, °æ±¸°¨¿°
  • primary infection
    ÀÏÂ÷°¨¿°
  • protozoan infection
    ¿øÃæ°¨¿°
  • secondary infection
    ÀÌÂ÷°¨¿°
  • systemic infection
    Àü½Å°¨¿°
  • vaginal infection
    Áú°¨¿°
  • wound infection
    »ó󰨿°
  • infection route
    °¨¿°°æ·Î
  • infection source
    °¨¿°¿ø, Àü¿°¿ø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • observational study
    °üÂû¿¬±¸
  • pilot study
    ¿¹ºñ½ÇÇè
  • population study
    Àα¸Á¶»ç
  • preclinical study
    ÀÓ»óÀü½ÃÇè
  • pressure flow study
    ¾Ð·Â¿ä·ù°Ë»ç
  • pressure-perfusion study
    ¾Ð·Â°ü·ù°Ë»ç
  • professional activity study
    Àü¹®°¡È°µ¿¿¬±¸
  • prospective study
    °èȹ¿¬±¸, ÀüÇ⿬±¸, ¾Õ¹æÇ⿬±¸
  • real time study
    ½Ç½Ã°£°Ë»ç
  • retrospective study
    ÈÄÇ⿬±¸, µÞ¹æÇ⿬±¸
  • study
    ¿¬±¸, °Ë»ç
  • single blind study
    ´ÜÀϸͰ˹ý
  • survivorship study
    »ýÁ¸¿¬±¸
  • time study
    ½Ã°£¿¬±¸
  • tracer study
    ÃßÀûÀÚ¿¬±¸
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • quality control
    Á¤µµ°ü¸®
  • quality control
    ǰÁú°ü¸®(̰̤˴Ëö).
  • quality control
    È­Áú °ü¸®, ǰÁú°ü¸®
  • quality control program
    Á¤µµ°ü¸®°èȹ
  • quality control, QC
    ǰÁú°ü¸®, Á¤µµº¸Áõ, Á¤µµ°ü¸®
  • Borrelia recurrentis infection
    Àç±Í¿­±Õ °¨¿°.
  • Coxsackie virus infection
    ÄÛ»èŰ¹ÙÀÌ·¯½º°¨¿°.
  • Denal infection
    Ä¡¾Æ°¨¿°
  • ECHO virus infection
    ¿¡ÄÚ¹ÙÀÌ·¯½º°¨¿°.
  • ECHO virus infection
    ¿¡ÄÚ¹ÙÀÌ·¯½º°¨¿°.
  • Gag antigen in HIV infection
    HIV °¨¿°ÀÇ gag Ç׿ø
  • HIV infection
    HIV °¨¿°
  • HIV infection diagnosis
    HIV °¨¿°Áø´Ü
  • Hemophilus infection
    Çì¸ðÇʷ罺°¨¿°, È£Ç÷±Õ°¨¿°.
  • Infection
    °¨¿°(Êïæø)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • tracer study
    ÃßÀûÀÚ¿¬±¸(õÚîæíºæÚϼ).
  • twin study
    ½Ö»ý¾Æ¿¬±¸(¡­æÚϼ).
  • twin study
    ½Ö»ý¾Æ¿¬?¡­æÚϼ)
  • urodynamic study
    ¿ä¿ªµ¿ÇÐ °Ë»ç
  • validity of clinical study
  • video-urodynamic study
    ºñµ¥¿À ¿ä¿ªÇа˻ç
  • water-loading study
    ¼öºÐ-ºÎÇÏ ½ÃÇè
  • accuracy control
    Á¤È®¼º Á¶Àý
  • admission by legal control
    Á¶Ä¡ÀÔ¿ø.
  • air pollution control
    ´ë±â¿À¿°¹æÁö<±ÔÁ¦> (ÊÙËÑ̤<˻̡>).
  • awaking drug control law
    °¢¼ºÁ¦Á¶Àý¹ý.
  • biologics control
    »ý¹°Á¦Á¦°ËÁ¤(ÊÙÌ¡Ì¡Ë§Ëø).
  • biologics control
    »ý¹°Á¦Á¦°ËÁ¤(¡­ð²ð¥ËþïÒ).
  • biologics control laboratory
    [º´¸®,¹Ì»ý,±â»ý,¸é¿ª,¹ÙÀÌ,¿¹¹æ]»ý¹°Á¦Á¦°ü¸®½ÃÇè¼Ò(Ë×ËÑ̡̡˴ËöËàÌ´ËÛ).
  • biologics control laboratory
    º´¸®,¹Ì»ý,±â»ý,¸é¿ª,¹ÙÀÌ,¿¹¹æ»ý¹°Á¦Á¦°ü¸®½ÃÇè¼Ò(ßæÚªð²ð¥Î·ìµãËúÐá¶).
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • puerperal infection
    »ê¿å°¨¿°
  • pyogenic infection
    È­³ó¼º°¨¿°
  • secondary infection
    ÀÌÂ÷°¨¿°, ¼Ó¹ß°¨¿°
  • silent infection
    ¹«Áõ»ó°¨¿°
  • staphylococcal infection
    Æ÷µµ±¸±Õ°¨¿°
  • surgical infection
    ¿Ü°úÀû°¨¿°
  • systemic infection
    Àü½Å¼º°¨¿°(Áõ)
  • viral infection
    ¹ÙÀÌ·¯½º°¨¿°
  • water-borne infection
    ¼öÀμº°¨¿°, ¼öÀμºÀü¿°
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
BCM B-cell maturation; birth control medication; blood-clotting mechanism effects; body cell mass; body ...
CDC calculated date of confinement; cancer diagnosis center; capillary diffusion capacity; cell division...
URI Upper Respiratory Infection; »ó±âµµ °¨¿°
UTI Urinary Tract Infection; ºñ´¢±â°è °¨¿°
AFIS amniotic fluid infection syndrome
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
Control control
control group control
UTI 3-urinary tract infection
hpi 9h post infection
ARI Acute Respiratory Infection
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • control of bleeding
    ÁöÇ÷¹ý
  • control panel
    Á¶Á¾ÆÇ
  • control system
    Á¶Àý°è
  • control valve
    Á¶Àý ¹ëºê, Á¶ÀýÆÇ
  • laser hazard control measure
    ·¹ÀÌÀú À§ÇØÁ¶Àý¹ý
    ·¹ÀÌÀú°¡ Áö´Ñ ¾öû³­ ¿¡³ÊÁö´Â ÀÎü¿¡ ÇØ°¡ µÉ ¼ö ÀÖÀ¸¹Ç·Î µÇµµ·Ï ·¹ÀÌÀú¸¦ »ç¿ëÇÏ´Â »ç¶÷µéÀÌ ¼Õ»óÀ» ¹ÞÁö ¾Êµµ·Ï ÇÏ´Â ¹æ¹ý.
  • leprosy control
    ³ª °ü¸®
    °³³ä»ó, ÁÖ¹ÎÀ» ³ª±ÕÀÇ Àü¿°À¸·ÎºÎÅÍ º¸È£ÇÏ´Â ¿¹¹æ °ü¸®¿Í, ³ªÈ¯ÀÚ¸¦ ³ª±ÕÀ¸·ÎºÎÅÍ ¿À´Â À°Ã¼Àû, Á¤½ÅÀû °íÅëÀ» ´ú¾î ÁÖ´Â Áø·á °ü¸®ÀÇ µÎ °¡Áö·Î ºÐ·ùÇÒ ¼ö ÀÖ´Ù. ¨ç ¿¹¹æ °ü¸®´Â Àü¿°¿øÀ» Â÷´ÜÇÏ´Â °ÍÀ» ¸»Çϴµ¥, ³ª ȯÀÚ¸¦ °Ý¸®ÇÔÀ¸·Î½á ³ªº´ÀÇ Àü¿°¿øÀÌ Â÷´ÜµÈ´Ù°í »ý°¢Çß´ø ½Ã´ë¿¡´Â ³ª ȯÀÚ Àü¿øÀ» °Ý¸® ¼ö¿ëÇÏ¿´´Ù. ±×·¯³ª Àüü ³ª ȯÀÚ Áß ±ØÈ÷ ÀϺÎÀÇ ¹Ì°ü¸®ÇÏ¿¡ Àִ ȯÀÚ¸¸ÀÌ Àü¿°¿øÀÌ µÈ´Ù´Â »ç½ÇÀÌ ¹àÇôÁø ¿À´Ã³¯¿¡´Â, ³ª ȯÀÚ·Î È®ÀÎÀÌ µÇ¾î ¾àÁ¦ Åõ¿©°¡ ½ÃÀÛµÈ ÈÄ¿¡´Â Àü¿°¿øÀÌ µÉ ¼ö ¾ø´Ù´Â °á·Ð¿¡ À̸£·¶´Ù. ÀÌ¿¡ µû¶ó ¿À´Ã³¯¿¡´Â ÀÏ¹Ý ÇǺΠÁúȯÀÚ¿Í °°ÀÌ ÀÚÀ¯·ÎÀÌ »ý¾÷¿¡ Á¾»çÇϸç Áø·á¸¦ ¹Þ°í ÀÖ´Ù. ¨è Áø·á °ü¸®´Â Àǻ簡 Á¤È®ÇÑ Áø´Ü°ú º´Çü ºÐ·ù¸¦ ¹ÙÅÁÀ¸·Î ÀûÇÕÇÑ Ã³¹æÀ» ³»¸®°í ȯÀÚ°¡ ¼º½ÇÇÏ°Ô ¾àÀ» º¹¿ëÇÏ´Â °ÍÀÌ´Ù. ¹®Á¦´Â ³ªº´ÀÌ ¸¸¼ºÀûÀ¸·Î °æ°úÇÏ´Â Àå±â ÁúȯÀε¥´Ù Ä¡·áÀÇ ¼º°ú°¡ Áï½Ã ³ªÅ¸³ªÁö ¾ÊÀ¸¹Ç·Î 󹿰ú º¹¾àÀÌ ³ªÅÂÇØÁ® Ä¡·á°¡ ºÒ±ÔÄ¢ÇØÁö°í ¾àÁ¦ ³»¼ºÀ» ¹ßÀü½ÃŰ´Â µ¥ µû¸¥ °ü¸®»óÀÇ ¾î·Á¿òÀÌ ÀÖ´Ù. ³ªº´¿¡ ´ëÇÑ Æí°ßÀ» ¾ø¾Ö°í ±¹¹ÎÀû ÀÌÇØ¿Í Âü¿©¿¡ ÀÇÇØ Á¶±â ¹ß°ß ¹× Ä¡·á¿¡ ÀÓÇÑ´Ù¸é ³ªº´ °ü¸®¸¦ À§ÇÑ Æ¯¼ö ½Ã¼³À̳ª ±â°üÀÌ ÇÊ¿ä¾ø°Ô µÉ °ÍÀÌ´Ù.
  • nociceptive control
    Ä§ÇØ ¼ö¿ë¼º Á¶Àý, À¯ÇØ ¼ö¿ë¼º Á¶Àý
  • pest control
    À¯ÇØ »ý¹° Á¦¾î
  • plaque control
    ġŠÁ¶Àý
  • proper direction and control
    ÀûÀýÇÑ Áöµµ¿Í ÅëÁ¦
  • pulse control unit
    ¸Æ¹Ú Á¶Àý ´ÜÀ§
  • quality control program
    Á¤µµ °ü¸® °èȹ
  • reasonable emotional control
    ÇÕ¸®Àû Á¤¼­ Á¶Àý
  • regular control
    ±ÔÄ¢ÀûÀÎ Á¶Àý
  • self-control
    ÀÚ°¡ Á¶Àý¹ý
    °³ÀÎÀÇ ½Å³ä ¸ñÇ¥ ¹× ŵµ¿¡ µû¶ó¼­ ÀÚ±âÀÇ ÇൿÀ» ½º½º·Î Á¶ÀýÇÏ´Â °Í.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
foetal doppler study <radiology> Non-stress test (NST), external monitoring for 20 minutes; poor specificity, greater than4 foetal heart accelerations (greater than15 bpm over baseline for 15 seconds) following foetal movement in foetus greater than34 weeks, no heart accelerations in immaturity, sleep, maternal sedation contraction stress test (CST), external monitoring after oxytocin or maternal breast stimulation, greater than 3 uterine contraction in 10 minutes; 50% specificity uterine and umbilical artery waveform, elevated systolic:diastolic ratio = increased vascular resistance foetal aortic flow volume, 185-246 ml/kg/min see also: biophysical profile, intrauterine growth retardation (IUGR)
(12 Dec 1998)
follow-up study Study in which persons exposed to risk or given a designated preventive or therapeutic regimen are observed over a period or at intervals to determine the outcome of the exposure or regimen.
(05 Mar 2000)
Framingham Heart study <epidemiology> Ongoing epidemiologic study of a cohort of over 5,000 of the population of Framingham, MA conducted since 1949 under the auspices of the National Institutes of Health and Boston University.
(05 Mar 2000)
longitudinal study <epidemiology> A study taking place over time. If individuals are followed, this is a longitudinal cohort study. If individuals are not followed, but classes (usually age classes) are restudied, this is a longitudinal cross-sectional study.
The converse of a horizontal study.
(05 Dec 1998)
agonal infection An acute infection, commonly pneumonic or septic, occurring toward the end of any disease and often the cause of death.
Synonym: agonal infection.
(05 Mar 2000)
airborne infection A mechanism of transmission of an infectious agent by particles, dust, or droplet nuclei suspended in the air.
(05 Mar 2000)
apical infection Implantation of microorganisms at the apex of a tooth, usually the result of the migration of microorganisms from the pulp canal through the apical foramen.
(05 Mar 2000)
arbovirus infection <virology> A type of viral infection that is transmitted by mosquitoes in late spring to early autumn. One manifestation is encephalitis (central nervous system infection).
(27 Sep 1997)
ascariasis infection <microbiology> Infection by the nematode Ascaris lumbricoides and is characterised by an early pulmonary phase related to larval migration and a later, prolonged intestinal phase.
Adult worms are 15-40 cm in length and maintain themselves in the lumen of the small intestine. Infection occurs after ingesting eggs contained in contaminated food or more commonly, by transmission to the mouth by the hands after contact with contaminated soil.
Treatment is with mebendazole or pyrantel pamoate.
(27 Sep 1997)
atypical mycobacterial infection <microbiology> Infection with organisms from the Mycobacterium genus other than tuberculosis.
Risk factors include immunocompromised patients and those with AIDS. Mycobacterium avium intracellulare is an example which frequently infects AIDS patients.
Atypical mycobacterial infections can cause abscesses, septic arthritis and osteomyelitis.
Treatment can be difficult due to the emergence of resistance to standard antitubercular antibiotics.
(27 Sep 1997)
bacterial infection <microbiology> Bacteria are group of micro-organisms that are a single cell approximately 1 micron in transverse diameter. Some bacteria cause disease in man, requiring treatment with an antibiotic.
(27 Sep 1997)
bladder infection Some people are at more risk for bladder and other urinary tract infections (UTIs) than others. One woman in five develops a UTI during her lifetime. Not everyone with a UTI has symptoms. Common symptoms include a frequent urge to urinate and a painful, burning when urinating. Underlying conditions that impair the normal urinary flow can lead to more complicated UTIs.
(12 Dec 1998)
breast infection <microbiology> Inflammation of the breast tissue most often caused by a bacterial infection.
Staphylococcus is the most common organism. This breast infection is seen most commonly in the immediate postpartum period (during breast-feeding).
Treatment includes warm wet compresses to the site and oral antibiotics.
(27 Sep 1997)
parasitic infection <microbiology> A successful invasion of a host by an organism that uses the host for food and shelter.
(27 Sep 1997)
germinal infection Infection of a baby with a disease by way of a parent's gamete (sperm or ovum).
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • control chart
    °ü¸®µµ(ƯÈ÷ Á¦Ç° ǰÁúÀÇ)
  • control clock
    ±âÁØ ½Ã°è(master clock)
  • control column
    Á¶Á¾·û(Â÷ÀÇ ÇÚµé½Ä Á¶Á¤°£)
  • control experiment
    ´ëÁ¶ ½ÇÇè
  • control grid
    (ÀüÀÚ°üÀÇ)Á¦¾î ±×¸®µå(°ÝÀÚ)
  • control group
    Á¦¾îÁý´Ü;Á¶Á¾ÀåÄ¡;´ëÁ¶±º(µ¿ÀϽÇÇè¿¡¼­ ½ÇÇè¿ä°ÇÀ» °¡ÇÏÁö ¾ÊÀº ±×·ì)
  • control lever
    =CONTROL STICK
  • control panel
    =CONTROL BOARD
  • control rod
    (¿øÀÚ·ÎÀÇ)Á¦¾îºÀ
  • control room
    °üÁ¦½Ç;(¿øÀڷ½ü³µîÀÇ)Á¦¾î½Ç;(¹æ¼Û±¹µîÀÇ)Á¶Á¤½Ç
  • control stick
    Á¶Á¾°£
  • control storage
    Á¦¾î±â¾ïÀåÄ¡
  • control tower
    (°øÇ×ÀÇ)°üÁ¦Å¾
  • damage control
    ÀÀ±Þ ÇÇÇØ ´ëÃ¥;ÇÇÇØ ´ëÃ¥¹Ý
  • dual control
    ÀÌÁß °üÇÒ;¾ç±¹ °øµ¿ ÅëÄ¡;(°ø)ÀÌÁß Á¶Á¾ ÀåÄ¡
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á